Thrombotic Thrombocytopenic Purpura (Moschcowitz Disease) Global Clinical Trials Review, H2, 2018
- GDHC5226CTIDB
- Pages: 74
- August 2018
- Total Views:1130
- Region : Global
- GlobalData
- Market Research Report
Details
Thrombotic Thrombocytopenic Purpura (Moschcowitz Disease) Global Clinical Trials Review, H2, 2018
Summary
GlobalData's clinical trial report, Thrombotic Thrombocytopenic Purpura (Moschcowitz Disease) Global Clinical Trials Review, H2, 2018" provides an overview of Thrombotic Thrombocytopenic Purpura (Moschcowitz Disease) clinical trials scenario. This report provides top line data relating to the clinical trials on Thrombotic Thrombocytopenic Purpura (Moschcowitz Disease). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database-Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.
The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.
*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- The report provides a snapshot of the global clinical trials landscape
- Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
- The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
- The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
- The Report provides enrollment trends for the past five years
- Report provides latest news for the past three months
*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Reasons to buy
- Assists in formulating key business strategies with regards to investment
- Helps in identifying prominent locations for conducting clinical trials which saves time and cost
- Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
- Supports understanding of trials count and enrollment trends by country in global therapeutics market
- Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
- Facilitates clinical trial assessment of the indication on a global, regional and country level
*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Table Of Content
Scope
Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 4
Report Guidance 5
GlobalData Clinical Trials Report Coverage 6
Clinical Trials by Region 7
Clinical Trials and Average Enrollment by Country 8
Top Five Countries Contributing to Clinical Trials in Asia-Pacific 11
Top Five Countries Contributing to Clinical Trials in Europe 12
Top Countries Contributing to Clinical Trials in North America 13
Top Countries Contributing to Clinical Trials in Middle East and Africa 14
Clinical Trials by G7 Countries: Proportion of Thrombotic Thrombocytopenic Purpura (Moschcowitz Disease) to Hematological Disorders Clinical Trials 15
Clinical Trials by Phase in G7 Countries 17
Clinical Trials in G7 Countries by Trial Status 18
Clinical Trials by E7 Countries: Proportion of Thrombotic Thrombocytopenic Purpura (Moschcowitz Disease) to Hematological Disorders Clinical Trials 20
Clinical Trials by Phase in E7 Countries 22
Clinical Trials in E7 Countries by Trial Status 23
Clinical Trials by Phase 24
In Progress Trials by Phase 25
Clinical Trials by Trial Status 26
Clinical Trials by End Point Status 28
Subjects Recruited Over a Period of Time 29
Clinical Trials by Sponsor Type 30
Prominent Sponsors 31
Top Companies Participating in Thrombotic Thrombocytopenic Purpura (Moschcowitz Disease) Therapeutics Clinical Trials 33
Prominent Drugs 35
Clinical Trial Profile Snapshots 37
Appendix 72
Abbreviations 72
Definitions 72
Research Methodology 73
Secondary Research 73
About GlobalData 73
Contact Us 74
Disclaimer 74
Source 74
List Of Figure
List of Figures
Thrombotic Thrombocytopenic Purpura (Moschcowitz Disease) Therapeutics, Global, Clinical Trials by Region (%), 2018* 7
Thrombotic Thrombocytopenic Purpura (Moschcowitz Disease) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2018* 8
Thrombotic Thrombocytopenic Purpura (Moschcowitz Disease) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2018* 10
Thrombotic Thrombocytopenic Purpura (Moschcowitz Disease) Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2018* 11
Thrombotic Thrombocytopenic Purpura (Moschcowitz Disease) Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2018* 12
Thrombotic Thrombocytopenic Purpura (Moschcowitz Disease) Therapeutics Clinical Trials, North America, Top Countries (%), 2018* 13
Thrombotic Thrombocytopenic Purpura (Moschcowitz Disease) Therapeutics Clinical Trials, Middle East and Africa, Top Countries (%), 2018* 14
Proportion of Thrombotic Thrombocytopenic Purpura (Moschcowitz Disease) to Hematological Disorders Clinical Trials, G7 Countries (%), 2018* 15
Thrombotic Thrombocytopenic Purpura (Moschcowitz Disease) Therapeutics, G7 Countries, Clinical Trials by Phase, 2018* 17
Thrombotic Thrombocytopenic Purpura (Moschcowitz Disease) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2018* 18
Proportion of Thrombotic Thrombocytopenic Purpura (Moschcowitz Disease) to Hematological Disorders Clinical Trials, E7 Countries (%), 2018* 20
Thrombotic Thrombocytopenic Purpura (Moschcowitz Disease) Therapeutics, E7 Countries, Clinical Trials by Phase, 2018* 22
Thrombotic Thrombocytopenic Purpura (Moschcowitz Disease) Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2018* 23
Thrombotic Thrombocytopenic Purpura (Moschcowitz Disease) Therapeutics, Global, Clinical Trials by Phase (%), 2018* 24
Thrombotic Thrombocytopenic Purpura (Moschcowitz Disease) Therapeutics, Global, Clinical Trials In Progress by Phase, 2018* 25
Thrombotic Thrombocytopenic Purpura (Moschcowitz Disease) Therapeutics, Global, Clinical Trials by Trial Status, 2018* 26
Thrombotic Thrombocytopenic Purpura (Moschcowitz Disease) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2013-2017 29
Thrombotic Thrombocytopenic Purpura (Moschcowitz Disease) Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2018* 30
Thrombotic Thrombocytopenic Purpura (Moschcowitz Disease) Therapeutics Clinical Trials, Global, Key Sponsors, 2018* 31
Thrombotic Thrombocytopenic Purpura (Moschcowitz Disease) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2018* 33
Thrombotic Thrombocytopenic Purpura (Moschcowitz Disease) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2018* 35
GlobalData Methodology 73
List Of Table
List of Tables
Thrombotic Thrombocytopenic Purpura (Moschcowitz Disease) Therapeutics, Global, Clinical Trials by Region, 2018* 7
Thrombotic Thrombocytopenic Purpura (Moschcowitz Disease) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2018* 9
Thrombotic Thrombocytopenic Purpura (Moschcowitz Disease) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2018* 10
Thrombotic Thrombocytopenic Purpura (Moschcowitz Disease) Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2018* 11
Thrombotic Thrombocytopenic Purpura (Moschcowitz Disease) Therapeutics Clinical Trials, Europe, Top Five Countries, 2018* 12
Thrombotic Thrombocytopenic Purpura (Moschcowitz Disease) Therapeutics Clinical Trials, North America, Top Countries, 2018* 13
Thrombotic Thrombocytopenic Purpura (Moschcowitz Disease) Therapeutics Clinical Trials, Middle East and Africa, Top Countries, 2018* 14
Proportion of Thrombotic Thrombocytopenic Purpura (Moschcowitz Disease) to Hematological Disorders Clinical Trials, G7 Countries (%), 2018* 16
Thrombotic Thrombocytopenic Purpura (Moschcowitz Disease) Therapeutics, G7 Countries, Clinical Trials by Phase, 2018* 17
Thrombotic Thrombocytopenic Purpura (Moschcowitz Disease) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2018* 19
Proportion of Thrombotic Thrombocytopenic Purpura (Moschcowitz Disease) to Hematological Disorders Clinical Trials, E7 Countries (%), 2018* 21
Thrombotic Thrombocytopenic Purpura (Moschcowitz Disease) Therapeutics, E7 Countries, Clinical Trials by Phase, 2018* 22
Thrombotic Thrombocytopenic Purpura (Moschcowitz Disease) Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2018* 23
Thrombotic Thrombocytopenic Purpura (Moschcowitz Disease) Therapeutics, Global, Clinical Trials by Phase, 2018* 24
Thrombotic Thrombocytopenic Purpura (Moschcowitz Disease) Therapeutics, Global, Clinical Trials In Progress by Phase 2018* 25
Thrombotic Thrombocytopenic Purpura (Moschcowitz Disease) Therapeutics, Global, Clinical Trials by Trial Status, 2018* 27
Thrombotic Thrombocytopenic Purpura (Moschcowitz Disease) Therapeutics Clinical Trials, Global, by End Point Status, 2018* 28
Thrombotic Thrombocytopenic Purpura (Moschcowitz Disease) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2013-2017 29
Thrombotic Thrombocytopenic Purpura (Moschcowitz Disease) Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2018* 30
Thrombotic Thrombocytopenic Purpura (Moschcowitz Disease) Therapeutics Clinical Trials, Global, Key Sponsors, 2018* 32
Thrombotic Thrombocytopenic Purpura (Moschcowitz Disease) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2018* 34
Thrombotic Thrombocytopenic Purpura (Moschcowitz Disease) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2018* 36
Licence Rights
Single User License:
Report can be used by individual purchaser only
Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office
Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company
Section Purchase
INQUIRE FOR COVID-19 IMPACT ANALYSIS
Products and Companies
Products
Thrombotic Thrombocytopenic Purpura (Moschcowitz Disease) Clinical Trials, Phase, Completed, Ongoing, Planned, End Points, Trial Locations, Trial Designs, Subjects Recruited, Safety, Efficacy, Bioequivalence, Pharmacokinetics, Pharmacodynamic, Sponsor, Collaborator, CRO's, Terminated, Suspended and Withdrawn trials of Thrombotic Thrombocytopenic Purpura (Moschcowitz Disease), Pfizer, AstraZeneca, Novartis, GlaxoSmithKline, Sanofi, Eli Lilly and Company, Johnson & Johnson, Merck & Co., Inc, Bristol-Myers Squibb Company, Abbott Laboratories, Hoffmann-La Roche Ltd., Celgene Corporation, Daiichi Sankyo Company, Ltd., Bayer AG, Eisai Inc., GE Healthcare, Biogen Idec Inc., Copharos Inc., Wyeth Pharmaceuticals Inc., National Cancer Center, The University of Texas M. D. Anderson Cancer Center, Vanderbilt Medical Center, Memorial Sloan Kettering Cancer Center, Cancer Research UK, North Central Cancer Group, Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Fred Hutchinson Cancer Research Center, European Organization for Research and Treatment of Cancer, Dana-Farber Cancer Institute, The Cancer and Leukemia Group B, Columbia University, UCLA's Jonsson Comprehensive Cancer Center, Case Comprehensive Cancer Center, Mayo Clinic, Duke University, Ohio State University, University of Pennsylvania
Companies
Sanofi
Octapharma AG
Shire Plc
F. Hoffmann-La Roche Ltd
Pharm-Olam International Ltd
Biogen Inc
Archemix Corp
Amgen Inc
CSL Ltd
Canadian Apheresis Group
Company Profile
Company Profile Title
Thrombotic Thrombocytopenic Purpura (Moschcowitz Disease) Global Clinical Trials Review, H2, 2018
Summary
GlobalData's clinical trial report, Thrombotic Thrombocytopenic Purpura (Moschcowitz Disease) Global Clinical Trials Review, H2, 2018" provides an overview of Thrombotic Thrombocytopenic Purpura (Moschcowitz Disease) clinical trials scenario. This report provides top line data relating to the clinical trials on Thrombotic Thrombocytopenic Purpura (Moschcowitz Disease). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database-Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.
The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.
*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- The report provides a snapshot of the global clinical trials landscape
- Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
- The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
- The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
- The Report provides enrollment trends for the past five years
- Report provides latest news for the past three months
*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Reasons to buy
- Assists in formulating key business strategies with regards to investment
- Helps in identifying prominent locations for conducting clinical trials which saves time and cost
- Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
- Supports understanding of trials count and enrollment trends by country in global therapeutics market
- Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
- Facilitates clinical trial assessment of the indication on a global, regional and country level
*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 4
Report Guidance 5
GlobalData Clinical Trials Report Coverage 6
Clinical Trials by Region 7
Clinical Trials and Average Enrollment by Country 8
Top Five Countries Contributing to Clinical Trials in Asia-Pacific 11
Top Five Countries Contributing to Clinical Trials in Europe 12
Top Countries Contributing to Clinical Trials in North America 13
Top Countries Contributing to Clinical Trials in Middle East and Africa 14
Clinical Trials by G7 Countries: Proportion of Thrombotic Thrombocytopenic Purpura (Moschcowitz Disease) to Hematological Disorders Clinical Trials 15
Clinical Trials by Phase in G7 Countries 17
Clinical Trials in G7 Countries by Trial Status 18
Clinical Trials by E7 Countries: Proportion of Thrombotic Thrombocytopenic Purpura (Moschcowitz Disease) to Hematological Disorders Clinical Trials 20
Clinical Trials by Phase in E7 Countries 22
Clinical Trials in E7 Countries by Trial Status 23
Clinical Trials by Phase 24
In Progress Trials by Phase 25
Clinical Trials by Trial Status 26
Clinical Trials by End Point Status 28
Subjects Recruited Over a Period of Time 29
Clinical Trials by Sponsor Type 30
Prominent Sponsors 31
Top Companies Participating in Thrombotic Thrombocytopenic Purpura (Moschcowitz Disease) Therapeutics Clinical Trials 33
Prominent Drugs 35
Clinical Trial Profile Snapshots 37
Appendix 72
Abbreviations 72
Definitions 72
Research Methodology 73
Secondary Research 73
About GlobalData 73
Contact Us 74
Disclaimer 74
Source 74
List Of Figure
List of Figures
Thrombotic Thrombocytopenic Purpura (Moschcowitz Disease) Therapeutics, Global, Clinical Trials by Region (%), 2018* 7
Thrombotic Thrombocytopenic Purpura (Moschcowitz Disease) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2018* 8
Thrombotic Thrombocytopenic Purpura (Moschcowitz Disease) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2018* 10
Thrombotic Thrombocytopenic Purpura (Moschcowitz Disease) Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2018* 11
Thrombotic Thrombocytopenic Purpura (Moschcowitz Disease) Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2018* 12
Thrombotic Thrombocytopenic Purpura (Moschcowitz Disease) Therapeutics Clinical Trials, North America, Top Countries (%), 2018* 13
Thrombotic Thrombocytopenic Purpura (Moschcowitz Disease) Therapeutics Clinical Trials, Middle East and Africa, Top Countries (%), 2018* 14
Proportion of Thrombotic Thrombocytopenic Purpura (Moschcowitz Disease) to Hematological Disorders Clinical Trials, G7 Countries (%), 2018* 15
Thrombotic Thrombocytopenic Purpura (Moschcowitz Disease) Therapeutics, G7 Countries, Clinical Trials by Phase, 2018* 17
Thrombotic Thrombocytopenic Purpura (Moschcowitz Disease) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2018* 18
Proportion of Thrombotic Thrombocytopenic Purpura (Moschcowitz Disease) to Hematological Disorders Clinical Trials, E7 Countries (%), 2018* 20
Thrombotic Thrombocytopenic Purpura (Moschcowitz Disease) Therapeutics, E7 Countries, Clinical Trials by Phase, 2018* 22
Thrombotic Thrombocytopenic Purpura (Moschcowitz Disease) Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2018* 23
Thrombotic Thrombocytopenic Purpura (Moschcowitz Disease) Therapeutics, Global, Clinical Trials by Phase (%), 2018* 24
Thrombotic Thrombocytopenic Purpura (Moschcowitz Disease) Therapeutics, Global, Clinical Trials In Progress by Phase, 2018* 25
Thrombotic Thrombocytopenic Purpura (Moschcowitz Disease) Therapeutics, Global, Clinical Trials by Trial Status, 2018* 26
Thrombotic Thrombocytopenic Purpura (Moschcowitz Disease) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2013-2017 29
Thrombotic Thrombocytopenic Purpura (Moschcowitz Disease) Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2018* 30
Thrombotic Thrombocytopenic Purpura (Moschcowitz Disease) Therapeutics Clinical Trials, Global, Key Sponsors, 2018* 31
Thrombotic Thrombocytopenic Purpura (Moschcowitz Disease) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2018* 33
Thrombotic Thrombocytopenic Purpura (Moschcowitz Disease) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2018* 35
GlobalData Methodology 73
List Of Table
List of Tables
Thrombotic Thrombocytopenic Purpura (Moschcowitz Disease) Therapeutics, Global, Clinical Trials by Region, 2018* 7
Thrombotic Thrombocytopenic Purpura (Moschcowitz Disease) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2018* 9
Thrombotic Thrombocytopenic Purpura (Moschcowitz Disease) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2018* 10
Thrombotic Thrombocytopenic Purpura (Moschcowitz Disease) Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2018* 11
Thrombotic Thrombocytopenic Purpura (Moschcowitz Disease) Therapeutics Clinical Trials, Europe, Top Five Countries, 2018* 12
Thrombotic Thrombocytopenic Purpura (Moschcowitz Disease) Therapeutics Clinical Trials, North America, Top Countries, 2018* 13
Thrombotic Thrombocytopenic Purpura (Moschcowitz Disease) Therapeutics Clinical Trials, Middle East and Africa, Top Countries, 2018* 14
Proportion of Thrombotic Thrombocytopenic Purpura (Moschcowitz Disease) to Hematological Disorders Clinical Trials, G7 Countries (%), 2018* 16
Thrombotic Thrombocytopenic Purpura (Moschcowitz Disease) Therapeutics, G7 Countries, Clinical Trials by Phase, 2018* 17
Thrombotic Thrombocytopenic Purpura (Moschcowitz Disease) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2018* 19
Proportion of Thrombotic Thrombocytopenic Purpura (Moschcowitz Disease) to Hematological Disorders Clinical Trials, E7 Countries (%), 2018* 21
Thrombotic Thrombocytopenic Purpura (Moschcowitz Disease) Therapeutics, E7 Countries, Clinical Trials by Phase, 2018* 22
Thrombotic Thrombocytopenic Purpura (Moschcowitz Disease) Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2018* 23
Thrombotic Thrombocytopenic Purpura (Moschcowitz Disease) Therapeutics, Global, Clinical Trials by Phase, 2018* 24
Thrombotic Thrombocytopenic Purpura (Moschcowitz Disease) Therapeutics, Global, Clinical Trials In Progress by Phase 2018* 25
Thrombotic Thrombocytopenic Purpura (Moschcowitz Disease) Therapeutics, Global, Clinical Trials by Trial Status, 2018* 27
Thrombotic Thrombocytopenic Purpura (Moschcowitz Disease) Therapeutics Clinical Trials, Global, by End Point Status, 2018* 28
Thrombotic Thrombocytopenic Purpura (Moschcowitz Disease) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2013-2017 29
Thrombotic Thrombocytopenic Purpura (Moschcowitz Disease) Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2018* 30
Thrombotic Thrombocytopenic Purpura (Moschcowitz Disease) Therapeutics Clinical Trials, Global, Key Sponsors, 2018* 32
Thrombotic Thrombocytopenic Purpura (Moschcowitz Disease) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2018* 34
Thrombotic Thrombocytopenic Purpura (Moschcowitz Disease) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2018* 36
Single User License:
Report can be used by individual purchaser only
Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office
Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company
INQUIRE FOR COVID-19 IMPACT ANALYSIS
Products
Thrombotic Thrombocytopenic Purpura (Moschcowitz Disease) Clinical Trials, Phase, Completed, Ongoing, Planned, End Points, Trial Locations, Trial Designs, Subjects Recruited, Safety, Efficacy, Bioequivalence, Pharmacokinetics, Pharmacodynamic, Sponsor, Collaborator, CRO's, Terminated, Suspended and Withdrawn trials of Thrombotic Thrombocytopenic Purpura (Moschcowitz Disease), Pfizer, AstraZeneca, Novartis, GlaxoSmithKline, Sanofi, Eli Lilly and Company, Johnson & Johnson, Merck & Co., Inc, Bristol-Myers Squibb Company, Abbott Laboratories, Hoffmann-La Roche Ltd., Celgene Corporation, Daiichi Sankyo Company, Ltd., Bayer AG, Eisai Inc., GE Healthcare, Biogen Idec Inc., Copharos Inc., Wyeth Pharmaceuticals Inc., National Cancer Center, The University of Texas M. D. Anderson Cancer Center, Vanderbilt Medical Center, Memorial Sloan Kettering Cancer Center, Cancer Research UK, North Central Cancer Group, Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Fred Hutchinson Cancer Research Center, European Organization for Research and Treatment of Cancer, Dana-Farber Cancer Institute, The Cancer and Leukemia Group B, Columbia University, UCLA's Jonsson Comprehensive Cancer Center, Case Comprehensive Cancer Center, Mayo Clinic, Duke University, Ohio State University, University of Pennsylvania
Companies
Sanofi
Octapharma AG
Shire Plc
F. Hoffmann-La Roche Ltd
Pharm-Olam International Ltd
Biogen Inc
Archemix Corp
Amgen Inc
CSL Ltd
Canadian Apheresis Group
Ask A Question
Our Team Will Assist You in What You Are Looking For
or 
: +91 98100 26150
: ankurgupta1984
Related Reports
Page 130 | 
December 2020
Page 130 | December 2020
Page 131 | November 2020
Page 95 | November 2020
Page 96 | August 2020